COMPANY PROFILE

JN Medsys is an innovative company in the medical technology industry, specializing in the development and manufacturing of cutting-edge medical devices and systems. Focused on innovation and quality, JN Medsys is rapidly gaining recognition by integrating advanced technologies into its products to enhance healthcare outcomes globally. The company was founded by Johnson Ng, who has extensive experience in entrepreneurship and medical device development and commercialization. Johnson graduated with a Bachelor of Engineering (First Class Honours) and doctorate degree from the National University of Singapore.

JN Medsys is recognized for its state-of-the-art digital PCR (dPCR) products, which represent a significant advancement in nucleic acid quantification technology. Digital PCR is a precise method used to quantify and genotype nucleic acids, offering advantages over traditional PCR methods by providing absolute quantification without relying on standard curves.

PRODUCT FEATURES

PRECISION AND SENSITIVITY

JN Medsys' digital PCR platforms are known for their high precision and sensitivity, enabling accurate quantification of target nucleic acids even at low concentrations. This is crucial for applications such as detecting rare mutations or monitoring viral load in clinical settings.

SCALABILITY

The dPCR systems ofered by JN Medsys are scalable, accommodating varying throughput needs from research laboratories to high-throughput clinical diagnostic settings. This flexibility makes them suitable for a wide range of applications, from basic research to routine diagnostics.

EASE OF USE

Designed with user-friendly interfaces and intuitive software, JN Medsys' dPCR instruments are accessible to both seasoned researchers and technicians new to digital PcR technology.This simplifies workflow and reduces the learning curve associated with adopting new technologies.

VERSATILITY

JN Medsys' dPCR platforms support a variety of applications beyond basic nucleic acid quantification, including copy number variation analysis, gene expression studies, and absolute quantification of viral RNA or DNA. This versatility makes them invaluable tools in molecular biology and clinical research.

APPLICATION AREA

CLINICAL DIAGNOSTICS: 

Used for detecting and monitoring genetic diseases, infectious diseases, and cancer biomarkers with high sensitivity and accuracy.

RESEARCH: 

Facilitates precise quantification of nucleic acids for gene expression analysis, mutation detection, and next-generation sequencing library quantification.

QUALITY CONTROL: 

Enables rigorous quality control in_biopharmaceutical production,ensuring consistency and reliability in product development.

INNOVATION AND FUTURE DEVELOPMENT DIRECTION

JN Medsys continues to innovate in the field of digital PCR, exploring enhancements in multiplexing capabilities, automation, and integration with other molecular diagnostic technologies. Their ongoing research and development efforts aim to further improve sensitivity, reduce costs, and expand the application scope of dPcR in both research and clinical settings. In summary, JN Medsys' digital PCR products stand at the forefront of molecular diagnostics, offering advanced solutions that empower researchers and healthcare professionals with precise, reliable tools for nucleic acid analysis.

Other incubated enterprises